Cerebrospinal fluid untargeted metabolomic profiling of aneurysmal subarachnoid hemorrhage: an exploratory study

Lu, Alex Y.; Damisah, Eyiyemisi; Winkler, Ethan A.; Grant, Ryan A.; Eid, Tore; Bulsara, Ketan R.

doi:10.1080/02688697.2018.1519107

Cited by 17 publications

(18 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The increase in free amino acids in CSF during hospitalization has also been proposed as a marker for the catabolism process. One study reported the L form of 2-hydroxyglutarate as a biomarker for hypoxia response during hemorrhagic brain events [ 175 ]. This metabolite increase reportedly predicted an adverse outcome, including leading to patients’ death [ 175 ].…”

Section: Metabolites In Specific Neurological Diseasesmentioning

confidence: 99%

“…One study reported the L form of 2-hydroxyglutarate as a biomarker for hypoxia response during hemorrhagic brain events [ 175 ]. This metabolite increase reportedly predicted an adverse outcome, including leading to patients’ death [ 175 ]. By contrast, decreased levels of the L form of 2-hydroxyglutarate have been associated with low disability among patients with HS [ 175 ].…”

Section: Metabolites In Specific Neurological Diseasesmentioning

confidence: 99%

“…This metabolite increase reportedly predicted an adverse outcome, including leading to patients’ death [ 175 ]. By contrast, decreased levels of the L form of 2-hydroxyglutarate have been associated with low disability among patients with HS [ 175 ]. Lu et al also reported that an increase in glycine and proline during hospitalization of patients with subarachnoid hemorrhage might induce meningeal collagen synthesis and serve as a biomarker of the disease [ 175 ].…”

Section: Metabolites In Specific Neurological Diseasesmentioning

confidence: 99%

“…Several studies have found abnormal levels of BCAA and its metabolites in patients with PD and stroke [ 6 , 143 , 145 , 168 , 175 ], and have been linked to neurodegenerative diseases [ 75 ]. BCAA is involved in the synthesis of proteins, energy production, and the synthesis of neurotransmitters, such as glutamate [ 104 ].…”

Section: Metabolites In Specific Neurological Diseasesmentioning

confidence: 99%

See 3 more Smart Citations

Circulating Metabolites as Potential Biomarkers for Neurological Disorders—Metabolites in Neurological Disorders

et al. 2020

View full text Add to dashboard Cite

There are, still, limitations to predicting the occurrence and prognosis of neurological disorders. Biomarkers are molecules that can change in different conditions, a feature that makes them potential tools to improve the diagnosis of disease, establish a prognosis, and monitor treatments. Metabolites can be used as biomarkers, and are small molecules derived from the metabolic process found in different biological media, such as tissue samples, cells, or biofluids. They can be identified using various strategies, targeted or untargeted experiments, and by different techniques, such as high-performance liquid chromatography, mass spectrometry, or nuclear magnetic resonance. In this review, we aim to discuss the current knowledge about metabolites as biomarkers for neurological disorders. We will present recent developments that show the need and the feasibility of identifying such biomarkers in different neurological disorders, as well as discuss relevant research findings in the field of metabolomics that are helping to unravel the mechanisms underlying neurological disorders. Although several relevant results have been reported in metabolomic studies in patients with neurological diseases, there is still a long way to go for the clinical use of metabolites as potential biomarkers in these disorders, and more research in the field is needed.

show abstract

Section: Metabolites In Specific Neurological Diseasesmentioning

confidence: 99%

Section: Metabolites In Specific Neurological Diseasesmentioning

confidence: 99%

Section: Metabolites In Specific Neurological Diseasesmentioning

confidence: 99%

Section: Metabolites In Specific Neurological Diseasesmentioning

confidence: 99%

See 2 more Smart Citations

Circulating Metabolites as Potential Biomarkers for Neurological Disorders—Metabolites in Neurological Disorders

et al. 2020

View full text Add to dashboard Cite

show abstract

“…More recently, the development of omics technology which can simultaneously measure thousands of molecules (e.g., metabolomics for analysis of metabolites) has been used to search for new targets in many disease states. However, the field of SAH research is still only beginning to explore the potential of broad metabolomic profiling of patients [14,15,16]. Instead, more targeted, hypothesis-driven research investigating changes in metabolites after SAH has been conducted.…”

Section: Introductionmentioning

confidence: 99%

Using Cerebral Metabolites to Guide Precision Medicine for Subarachnoid Hemorrhage: Lactate and Pyruvate

et al. 2019

View full text Add to dashboard Cite

Subarachnoid hemorrhage (SAH) is one of the deadliest types of strokes with high rates of morbidity and permanent injury. Fluctuations in the levels of cerebral metabolites following SAH can be indicators of brain injury severity. Specifically, the changes in the levels of key metabolites involved in cellular metabolism, lactate and pyruvate, can be used as a biomarker for patient prognosis and tailor treatment to an individual’s needs. Here, clinical research is reviewed on the usefulness of cerebral lactate and pyruvate measurements as a predictive tool for SAH outcomes and their potential to guide a precision medicine approach to treatment.

show abstract

CSF metabolomics alterations after aneurysmal subarachnoid hemorrhage: what do we know?

Schmidt

Thomé

et al. 2023

Acta Neurol Belg

View full text Add to dashboard Cite

Purpose The purpose of this mini review is to describe metabolomics in cerebrospinal fluid (CSF) and its potential in aneurysmal subarachnoid hemorrhage (aSAH). In brain injury, patients’ micro dialysis enables detecting biochemical change in brain tissue. Indicators for ischemia were detected such as lactate, pyruvate, glucose, and glutamate. In aSAH patients, the pathophysiology and the factor for poor outcome are not completely understood yet. Routine use of biomarkers in CSF, particularly in aSAH patients, is still lacking. Methods This mini review was performed on the role of metabolomics alterations after aneurysmal subarachnoid hemorrhage. Results We identified five clinical studies that addressed metabolomics in patients with aneurysmal subarachnoid hemorrhage. Conclusion There is increasing evidence suggesting that biomarkers can give insight in the pathogenesis and can serve as an outcome predictor. In this mini review, we present a brief overview of metabolomics profiling in neuroscience and wish to discuss the predictive and therapeutic value in aSAH patients.

show abstract

Cerebrospinal fluid untargeted metabolomic profiling of aneurysmal subarachnoid hemorrhage: an exploratory study

Cited by 17 publications

References 30 publications

Circulating Metabolites as Potential Biomarkers for Neurological Disorders—Metabolites in Neurological Disorders

Circulating Metabolites as Potential Biomarkers for Neurological Disorders—Metabolites in Neurological Disorders

Using Cerebral Metabolites to Guide Precision Medicine for Subarachnoid Hemorrhage: Lactate and Pyruvate

CSF metabolomics alterations after aneurysmal subarachnoid hemorrhage: what do we know?

Contact Info

Product

Resources

About